Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the first half ending September 30, 2023. For the first half ending September 30, 2022, the company expects net sales of JPY 36,900 million compared to previous guidance of JPY 35,500 million, operating profit of JPY 2,000 million compared to previous guidance of JPY 900 million, profit attributable to owners of parent of JPY 5,600 million compared to previous guidance of JPY 4,800 million and basic earnings per share of JPY 122.26 per share compared to previous guidance of JPY 104.09.